FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Palabras clave : 
FOSL1
Cholangiocarcinoma
Transcription factors
Genetics
Targeted therapies
Fecha de publicación : 
2021
Editorial : 
Elsevier
ISSN : 
0168-8278
Nota: 
This is an open access article under the CC BY-NC-ND license.
Cita: 
Vallejo-Blanco, A. (Adrián); Erice, O. (Oihane); Entrialgo-Cadierno, R. (Rodrigo); et al. "FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted". Journal of Hepatology. 75 (2), 2021, 363 - 376
Resumen
Understanding the molecular mechanisms involved in cholangiocarcinoma (bile duct cancer) development and progression stands as a critical step for the development of novel therapies. Through an inter-species approach, this study provides evidence of the clinical and functional role of the transcription factor FOSL1 in cholangiocarcinoma. Moreover, we report that downstream effectors of FOSL1 are susceptible to pharmacological inhibition, thus providing new opportunities for therapeutic intervention.

Ficheros en este ítem:
Vista previa
Fichero
PIIS016882782100235X.pdf
Descripción
Tamaño
2.89 MB
Formato
Adobe PDF


Estadísticas e impacto

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.